Back to News & Events

Symbiotic Health Wins Best in Show at 1st Pitch Competition

Symbiotic Health, Inc, a New York City based company and Center for Biotechnology client, was named “Best in Show” at the first of MABA’s 1st Pitch Life Science events in 2015, Symbiotic Health has developed a capsule to help kill Clostridium difficile (Cdiff) infection which causes severe, debilitating diarrhea, is the most frequent hospital-acquired infection in the US and an immediate public health threat that requires urgent and immediate action (CDC). The company’s pipeline includes a capsule microbiome therapeutic designed to cure Cdiff by restoring a community of protective bacteria.

Dr. Gerard Honig, CEO of Symbiotic Health, presented on behalf of the company. Stephen M. Goodman, Co-founder of Mid Atlantic Bio Angels and a partner at Pryor Cashman LLP in New York City, also a panelist at the event said Dr. Honig’s pitch and responses to questions demonstrated both mastery of the competitive space and a willingness to address challenges to his analysis calmly and directly. His style, as well as his substance, exemplified the maxim that it’s not just the business plan but the management that ultimately brings a company success. Read more about the company and the competition here.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4804
                    [post_author] => 4
                    [post_date] => 2025-03-20 12:10:54
                    [post_date_gmt] => 2025-03-20 16:10:54
                    [post_content] => 

The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.

The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.

The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.

Learn more about the program, get information session details and access the full request for proposals here: https://centerforbiotechnology.org/what-we-do/technology-development/reach/

[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards [post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => news-reach25 [to_ping] => [pinged] => [post_modified] => 2025-03-24 12:11:36 [post_modified_gmt] => 2025-03-24 16:11:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4804 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2899 [post_author] => 1 [post_date] => 2017-12-15 20:24:05 [post_date_gmt] => 2017-12-15 20:24:05 [post_content] => Clinton Rubin, PhD, Director of the Center for Biotechnology and Distinguished Professor of Biomedical Engineering at Stony Brook University has been elected as a Fellow of the National Academy of Inventors (NAI). According to the NAI, election as an NAI Fellow is a high honor bestowed upon academic innovators and inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions and innovations that have made a tangible impact on quality of life, economic development, and the welfare of society. Dr. Rubin and fellow SBU Distinguished Professor Dr. Arie Kaufman will be inducted as NAI Fellows during its 2018 national meeting in Washington, DC, on April 5. With the election of the 2017 class there are now 912 NAI Fellows, representing over 250 research universities and governmental and non-profit research institutes. The 2017 Fellows are named inventors on nearly 6,000 issued U.S. patents, bringing the collective patents held by all NAI Fellows to more than 32,000 issued U.S. patents. Professor Rubin, founding chair of Stony Brook’s Department of Biomedical Engineering, pioneered research in understanding the role of mechanical signals in the musculoskeletal system and has patented technology that includes use of low frequency mechanical signals (vibrations) to combat disease like osteoporosis and obesity. More on Dr. Rubin’s election as an NAI Fellow can be access here and here. [post_title] => CFB Director Elected Fellow, National Academy of Inventors (NAI) [post_excerpt] => Clinton Rubin, PhD, Director of the Center for Biotechnology has been elected a Fellow of the National Academy of Inventors (NAI). [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => cfb-director-elected-fellow-national-academy-of-inventors-nai [to_ping] => [pinged] => [post_modified] => 2018-01-23 14:38:34 [post_modified_gmt] => 2018-01-23 14:38:34 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2899 [menu_order] => 131 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 4373 [post_author] => 4 [post_date] => 2024-02-08 15:17:50 [post_date_gmt] => 2024-02-08 20:17:50 [post_content] =>

Save the date to join us in New York City for the expanded, two-day Life Sciences Summit™ 2024! Visit lifesciencessummit.org for program & registration updates.

[post_title] => Save the Date! LSS 2024: October 8-9th! [post_excerpt] => Save the date to join us in New York City for the expanded, two-day Life Sciences Summit™ 2024! [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => save-the-date-lss-2024-october-9th [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:48:53 [post_modified_gmt] => 2024-11-19 15:48:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4373 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [4] => WP_Post Object ( [ID] => 2486 [post_author] => 4 [post_date] => 2016-11-22 16:36:20 [post_date_gmt] => 2016-11-22 16:36:20 [post_content] => The application period for the SUNY Technology Accelerator Fund Class of 2017 is now open. The SUNY Technology Accelerator Fund (TAF) provides investments to support the advancement of SUNY innovations from the lab to the marketplace. TAF investments are made on a highly competitive basis in projects that target critical research and development milestones, such as feasibility studies, prototyping and testing, which demonstrate that an idea or innovation has commercial potential. Faculty, staff, and students from all disciplines and campuses are encouraged to submit proposals for the SUNY Technology Accelerator Fund Class of 2017 funding. The deadline for submitting proposals is March 20, 2017. See TAF Class of 2017 Application and Administrative Guidelines. Please be advised that all proposals require the review and participation of your campus administration prior to submission. To be certain that you adhere to any local proposal submission deadlines, you are urged to immediately contact your technology transfer office and/or office of sponsored programs if you are interested in applying for TAF Class of 2017 funding. Jointly funded by the State University of New York and the Research Foundation, the Technology Accelerator Fund has invested over $2 million since its launch in April 2011, and brought to life 36 of SUNY’s most promising technologies by catalyzing the investment of an additional $4.1 million from external partners, including federal agencies, industry licensees and angel investors. To learn about the technologies in which TAF has invested and the people who made it happen, see Technology Accelerator Funded Projects. Questions? Please send any questions to TAF@rfsuny.org. All questions and answers will be posted to www.rfsuny.org/taf. [post_title] => Funding Opportunity: SUNY Technology Accelerator Fund Accepting Proposals [post_excerpt] => The SUNY Technology Accelerator Fund (TAF) provides investments to support the advancement of SUNY innovations from the lab to the marketplace. The application period for the SUNY TAF Class of 2017 is now open. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => funding-opportunity-suny-technology-accelerator-fund-accepting-proposals [to_ping] => [pinged] => [post_modified] => 2016-11-30 15:19:35 [post_modified_gmt] => 2016-11-30 15:19:35 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2486 [menu_order] => 159 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 5 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4804 [post_author] => 4 [post_date] => 2025-03-20 12:10:54 [post_date_gmt] => 2025-03-20 16:10:54 [post_content] =>

The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.

The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.

The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.

Learn more about the program, get information session details and access the full request for proposals here: https://centerforbiotechnology.org/what-we-do/technology-development/reach/

[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards [post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => news-reach25 [to_ping] => [pinged] => [post_modified] => 2025-03-24 12:11:36 [post_modified_gmt] => 2025-03-24 16:11:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4804 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 267 [max_num_pages] => 89 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards

More Information

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

CFB Director Elected Fellow, National Academy of Inventors (NAI)

More Information

Save the Date! LSS 2024: October 8-9th!

More Information

Funding Opportunity: SUNY Technology Accelerator Fund Accepting Proposals

More Information